Canine Parvo Monoclonal Antibody (CPMA) Drug

We’re now offering the Canine Parvo Monoclonal Antibody (CPMA)—a groundbreaking, one-time IV injection that significantly reduces clinical symptoms of Parvo with a 100% efficacy rate. Most dogs show dramatic improvement within 24 hours, especially when treatment begins early. This is a game-changer in the fight against canine parvovirus.

Appointment

Owners whose dogs receive CPMA treatment are eligible for a $200 rebate, available now through December 31, 2025.

Canine Parvovirus Monoclonal Antibody (CPMA)

Canine parvovirus, commonly known as parvo, remains one of the leading causes of serious illness and death in dogs around the world. While vaccination is key to prevention, treatment options for infected dogs have been extremely limited—until now.

CPMA is the first and only USDA-conditionally approved, single-dose treatment for canine parvovirus. This breakthrough monoclonal antibody therapy offers new hope for dogs battling this life-threatening disease.

Think Your Dog Might Have Parvovirus? Don’t Wait—Treatment is Critical.

Canine parvovirus is a highly contagious and potentially fatal disease that attacks the intestinal lining. Without prompt treatment, it can quickly become life-threatening—especially in puppies and unvaccinated dogs.

If your dog shows any of the following signs, contact your veterinarian immediately:

  • Loss of appetite

  • Vomiting

  • Bloody or severe diarrhea

  • Abdominal pain

  • Lethargy

  • Fever

Early treatment saves lives. Ask your vet about Canine Parvovirus Monoclonal Antibody (CPMA)—a groundbreaking, single-dose therapy that can dramatically improve symptoms within 24 hours.